<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01023178</url>
  </required_header>
  <id_info>
    <org_study_id>SU-10272009-4262</org_study_id>
    <nct_id>NCT01023178</nct_id>
  </id_info>
  <brief_title>Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure</brief_title>
  <official_title>Comparison of Transdermal and Oral Estrogens in Adolescents With Ovarian Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To directly compare the safety (by laboratory evaluation) and efficacy (feminization and
      growth) of three commonly used estrogen preparations in adolescent patients with ovarian
      failure, either due to congenital causes (Turner syndrome) or medical therapies. We
      hypothesize that transdermal estrogen will have equivalent efficacy and a more favorable
      safety profile in comparison with conventional oral estrogen replacement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment with transdermal 17beta(17Î²) estradiol resulted in higher estradiol levels and more
      effective feminization compared to oral conjugated equine estrogen but did not result in an
      otherwise different biochemical profile in this limited number of heterogeneous patients. OBE
      (oral beta estradiol) and TBE (transdermal beta estradiol) provide safe and effective
      alternatives to OCEE (oral conjugated equine estrogen) to induce puberty in girls, but larger
      prospective randomized trials are required.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estradiol</measure>
    <time_frame>end of study (up to 2 years)</time_frame>
    <description>Estradiol blood levels at end of study compared across groups to determine effect of dosing methods. Significance of levels depends on the stage of puberty and goals of therapy.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Ovarian Failure, Premature</condition>
  <arm_group>
    <arm_group_label>Vivelle-Dot</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>17Beta Estradiol - transdermal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Premarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conjugated estrogens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estrace</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>17beta Estradiol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17beta Estradiol</intervention_name>
    <description>Oral pill given daily at increasing doses every 6 months for 18 months.</description>
    <arm_group_label>Estrace</arm_group_label>
    <other_name>Estrace</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conjugated estrogens</intervention_name>
    <description>Oral pill, started at a low dose taken daily, dose increased every 6 months for 18 months</description>
    <arm_group_label>Premarin</arm_group_label>
    <other_name>Premarin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17Beta Estradiol - transdermal</intervention_name>
    <description>Transdermal estrogen patch, started at low dose with increasing doses eery 6 months for 18 months</description>
    <arm_group_label>Vivelle-Dot</arm_group_label>
    <other_name>Vivelle-Dot</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone, micronized</intervention_name>
    <description>Given starting at 18 months</description>
    <arm_group_label>Vivelle-Dot</arm_group_label>
    <arm_group_label>Premarin</arm_group_label>
    <arm_group_label>Estrace</arm_group_label>
    <other_name>Prometrium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: in whom initiation of estrogen therapy has been recommended due to
        ovarian failure

          -  Outpatients

          -  age &gt;=12 years to 17.99 years old

        Exclusion Criteria:

          -  spontaneous menses

          -  significant concurrent medical problem including:

          -  Liver function tests (LFTs) 3 times normal

          -  clotting disorder

          -  ongoing cancer treatment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darrell M Wilson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>E Kirk Neely</last_name>
    <role>Study Director</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sejal Shah</last_name>
    <role>Sub-Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2009</study_first_submitted>
  <study_first_submitted_qc>November 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <results_first_submitted>July 16, 2014</results_first_submitted>
  <results_first_submitted_qc>November 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 20, 2017</results_first_posted>
  <last_update_submitted>November 28, 2016</last_update_submitted>
  <last_update_submitted_qc>November 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Darrell M Wilson</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>from 2007-2011 study participants were recruited from pediatric endocrinology clinics at Lucile Packard Children's Hospital at Stanford.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Transdermal 17Beta Estradiol</title>
          <description>17Beta Estradiol - transdermal: Transdermal estrogen patch, started at low dose with increasing doses eery 6 months for 18 months
Progesterone, micronized: Given starting at 18 months</description>
        </group>
        <group group_id="P2">
          <title>Oral Conjugated Equine Estrogen</title>
          <description>Conjugated estrogens: Oral pill, started at a low dose taken daily, dose increased every 6 months for 18 months
Progesterone, micronized: Given starting at 18 months</description>
        </group>
        <group group_id="P3">
          <title>Oral 17beta Estradiol</title>
          <description>17beta Estradiol: Oral pill given daily at increasing doses every 6 months for 18 months.
Progesterone, micronized: Given starting at 18 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Transdermal 17Beta Estradiol</title>
          <description>17Beta Estradiol - transdermal: Transdermal estrogen patch, started at low dose with increasing doses eery 6 months for 18 months
Progesterone, micronized: Given starting at 18 months</description>
        </group>
        <group group_id="B2">
          <title>Oral Conjugated Equine Estrogen</title>
          <description>Conjugated estrogens: Oral pill, started at a low dose taken daily, dose increased every 6 months for 18 months
Progesterone, micronized: Given starting at 18 months</description>
        </group>
        <group group_id="B3">
          <title>Oral 17beta Estradiol</title>
          <description>17beta Estradiol: Oral pill given daily at increasing doses every 6 months for 18 months.
Progesterone, micronized: Given starting at 18 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.2" spread="0.5"/>
                    <measurement group_id="B2" value="13.8" spread="0.4"/>
                    <measurement group_id="B3" value="14.5" spread="0.6"/>
                    <measurement group_id="B4" value="14.2" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Follicle Stimulating Hormone (FSH)</title>
          <units>mIU/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76" lower_limit="1.5" upper_limit="144"/>
                    <measurement group_id="B2" value="86" lower_limit="0.027" upper_limit="197"/>
                    <measurement group_id="B3" value="71" lower_limit="0.656" upper_limit="144"/>
                    <measurement group_id="B4" value="78" lower_limit="0.027" upper_limit="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Luteinizing Hormone (LH)</title>
          <units>mIU/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14" lower_limit="0.15" upper_limit="26"/>
                    <measurement group_id="B2" value="26" lower_limit="0.009" upper_limit="86"/>
                    <measurement group_id="B3" value="13" lower_limit="0.041" upper_limit="26"/>
                    <measurement group_id="B4" value="18" lower_limit="0.009" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Estradiol</title>
        <description>Estradiol blood levels at end of study compared across groups to determine effect of dosing methods. Significance of levels depends on the stage of puberty and goals of therapy.</description>
        <time_frame>end of study (up to 2 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transdermal 17Beta Estradiol</title>
            <description>17Beta Estradiol - transdermal: Transdermal estrogen patch, started at low dose with increasing doses eery 6 months for 18 months
Progesterone, micronized: Given starting at 18 months</description>
          </group>
          <group group_id="O2">
            <title>Oral Conjugated Equine Estrogen</title>
            <description>Conjugated estrogens: Oral pill, started at a low dose taken daily, dose increased every 6 months for 18 months
Progesterone, micronized: Given starting at 18 months</description>
          </group>
          <group group_id="O3">
            <title>Oral 17beta Estradiol</title>
            <description>17beta Estradiol: Oral pill given daily at increasing doses every 6 months for 18 months.
Progesterone, micronized: Given starting at 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Estradiol</title>
          <description>Estradiol blood levels at end of study compared across groups to determine effect of dosing methods. Significance of levels depends on the stage of puberty and goals of therapy.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" spread="19"/>
                    <measurement group_id="O2" value="14" spread="5"/>
                    <measurement group_id="O3" value="12" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Transdermal 17Beta Estradiol</title>
          <description>17Beta Estradiol - transdermal: Transdermal estrogen patch, started at low dose with increasing doses eery 6 months for 18 months
Progesterone, micronized: Given starting at 18 months</description>
        </group>
        <group group_id="E2">
          <title>Oral Conjugated Equine Estrogen</title>
          <description>Conjugated estrogens: Oral pill, started at a low dose taken daily, dose increased every 6 months for 18 months
Progesterone, micronized: Given starting at 18 months</description>
        </group>
        <group group_id="E3">
          <title>Oral 17beta Estradiol</title>
          <description>17beta Estradiol: Oral pill given daily at increasing doses every 6 months for 18 months.
Progesterone, micronized: Given starting at 18 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sejal Shah MD</name_or_title>
      <organization>Stanford University</organization>
      <phone>6507235791</phone>
      <email>sshah2@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

